Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oncolytic viruses

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

National Institute for Health and Care Excellence NICE logo

NICE backs freer use of SGLT2 inhibitors for diabetes

Recommendation positions Invokana, Forxiga and Jardiance as first-line treatments

Boehringer Ingelheim headquarters

Boehringer crowdsources psychiatric research team

Collaboration with BioMed X aims to identify new treatment approaches

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear...

Blue Latitude Health

Roche Basel Switzerland

Roche gets first approval for PD-L1 inhibitor Tecentriq

Expects to launch bladder cancer treatment within the next two weeks

Novartis building

Novartis splits pharma unit as Epstein exits

Restructure sees creation of standalone cancer arm Novartis Oncology

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Research Partnership

National Institute for Health and Care Excellence NICE logo

NICE persuaded to back Praluent as well as Repatha

Comes after Sanofi follows Amgen in discounting the price of its drug

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...

Evoke Mind+Matter

- PMLiVE

Does safety sell medicines?

Is pharmacovigilance unnecessary policing or a strategic asset for pharma companies?

- PMLiVE

AbbVie boosts immuno-oncology pipeline with $685m Argenx deal

Buys rights to immuno-suppressive antibody and will fund further research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links